PROM1 and acute lymphoblastic leukemia: Herein, we set out to characterize the Fc-optimized CD133 mAb 293C3-SDIE for targeting CD133 in the treatment of B-ALL with the aim of expanding the selection of mAb-targeted antigens for B-ALL patients, especially in the context of B-ALL subpopulations highly expressing CD133.